Pharmaxis (PXSLY) Stock Price, News & Analysis

Company Overview

Pharmaxis Limited is an Australian biotechnology company focused on discovering and developing therapies for serious chronic diseases, with particular emphasis on cancer and fibrotic conditions. The company’s research programs target lysyl oxidase (LOX) enzymes, which are involved in tissue remodeling, fibrosis and tumor progression.

Pharmaxis has developed small-molecule LOX inhibitors, including PXS-5505 and PXS-6302, for potential applications such as cancer, myelofibrosis, wound healing and other fibrotic diseases. These programs are intended to address conditions in which abnormal tissue structure and scarring contribute to disease progression.

Historically, Pharmaxis commercialized Aridol, a diagnostic test used to assess airway hyper-responsiveness in asthma, and Bronchitol, an inhaled dry-powder mannitol therapy designed to help clear mucus from the lungs, including in people with cystic fibrosis. The company is headquartered in Australia and has pursued international development and commercialization opportunities through licensing and collaboration arrangements.

Key Stats

• Today's Range: $0.88 to $0.88
• 50-Day Range: $0.88 to $0.88
• 52-Week Range: $0.62 to $1.47
• Volume: N/A
• Average Volume: 1,000 shs
• Market Capitalization: $26.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:PXSLY
• CIK: 1301357
• Web: www.pharmaxis.com.au
• Phone: 61-2-9454-7200
• Fax: N/A
• Employees: 69
• Year Founded: 1998

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 2.82
• Current Ratio: 3.31
• Quick Ratio: 2.92

Sales & Book Value

• Annual Sales: $8.75 million
• Price / Sales: 3.03
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.04 per share
• Price / Book: 22.00

Miscellaneous

• Outstanding Shares: 30,150,000
• Free Float: N/A
• Market Cap: $26.53 million
• Optionable: Not Optionable
• Beta: 1.22